Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Chemotherapy and Radiotherapy for ES-SCLC
NCT06672133Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2029
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 3 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06672133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672133.